Status:
COMPLETED
Glucose-homeostasis After Endoscopic Sleeve Gastroplasty
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Obesity, Morbid
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Endoscopic sleeve gastroplasty (ESG) is a transoral endoscopic procedure that creates a tubular sleeve along the lesser curvature with a gastric volume of approximately 30%. Summarizing the available ...
Detailed Description
Endoscopic sleeve gastroplasty (ESG) is a transoral endoscopic procedure that utilizes full-thickness sutures extending from the prepyloric antrum to the gastroesophageal junction, creating a tubular ...
Eligibility Criteria
Inclusion
- Planned ESG
- Written informed consent
- Male or female sex
- Age 18-65 years
- BMI ≥ 40 kg/m2 OR
- BMI ≥ 35 kg/m2 and obesity-related comorbidities except type 2 diabetes
Exclusion
- Type 1 or Type 2 Diabetes
- Type 2 Diabetes according to pathological OGTT at visit 2
- Mandatory use of medical drugs that influence glucose metabolism
- Participant had bariatric procedures other than ESG
- Abdominal surgery influencing glucose metabolism
- Moderate to severe chronic kidney, liver, or pancreatic disease
- Pregnancy or breastfeeding
- Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
Key Trial Info
Start Date :
January 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 9 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04063098
Start Date
January 30 2020
End Date
May 9 2023
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Bern, Switzerland, 3010